Literature DB >> 29055459

Smoking and multiple sclerosis: A systematic review and meta-analysis using the Bradford Hill criteria for causation.

Michelle L Degelman1, Katya M Herman2.   

Abstract

BACKGROUND: Despite being one of the most common neurological disorders globally, the cause(s) of multiple sclerosis (MS) remain unknown. Cigarette smoking has been studied with regards to both the development and progression of MS. The Bradford Hill criteria for causation can contribute to a more comprehensive evaluation of a potentially causal risk factor-disease outcome relationship. The objective of this systematic review and meta-analysis was to assess the relationship between smoking and both MS risk and MS progression, subsequently applying Hill's criteria to further evaluate the likelihood of causal associations.
METHODS: The Medline, EMBASE, CINAHL, PsycInfo, and Cochrane Library databases were searched for relevant studies up until July 28, 2015. A random-effects meta-analysis was conducted for three outcomes: MS risk, conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (CDMS), and progression from relapsing-remitting multiple sclerosis (RRMS) to secondary-progressive multiple sclerosis (SPMS). Dose-response relationships and risk factor interactions, and discussions of mechanisms and analogous associations were noted. Hill's criteria were applied to assess causality of the relationships between smoking and each outcome. The effect of second-hand smoke exposure was also briefly reviewed.
RESULTS: Smoking had a statistically significant association with both MS risk (conservative: OR/RR 1.54, 95% CI [1.46-1.63]) and SPMS risk (HR 1.80, 95% CI [1.04-3.10]), but the association with progression from CIS to CDMS was non-significant (HR 1.13, 95% CI [0.73-1.76]). Using Hill's criteria, there was strong evidence of a causal role of smoking in MS risk, but only moderate evidence of a causal association between smoking and MS progression. Heterogeneity in study designs and target populations, inconsistent results, and an overall scarcity of studies point to the need for more research on second-hand smoke exposure in relation to MS prior to conducting a detailed meta-analysis.
CONCLUSION: This first review to supplement systematic review and meta-analytic methods with Hill's criteria to analyze the smoking-MS association provides evidence supporting the causal involvement of smoking in the development and progression of MS. Smoking prevention and cessation programs and policies should consider MS as an additional health risk when aiming to reduce smoking prevalence in the population.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bradford Hill; Cigarette smoking; Clinically isolated syndrome; Epidemiology; Multiple sclerosis

Mesh:

Year:  2017        PMID: 29055459     DOI: 10.1016/j.msard.2017.07.020

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  32 in total

Review 1.  Immune and autonomic nervous system interactions in multiple sclerosis: clinical implications.

Authors:  Mario Habek
Journal:  Clin Auton Res       Date:  2019-04-08       Impact factor: 4.435

2.  Antisense modulation of IL7R splicing to control sIL7R expression in human CD4+ T cells.

Authors:  Gaddiel Galarza-Muñoz; Debbie Kennedy-Boone; Geraldine Schott; Shelton S Bradrick; Mariano A Garcia-Blanco
Journal:  RNA       Date:  2022-05-25       Impact factor: 5.636

Review 3.  Environmental risk factors in multiple sclerosis: bridging Mendelian randomization and observational studies.

Authors:  Marijne Vandebergh; Nicolas Degryse; Bénédicte Dubois; An Goris
Journal:  J Neurol       Date:  2022-04-02       Impact factor: 6.682

4.  The replication crisis in epidemiology: snowball, snow job, or winter solstice?

Authors:  Timothy L Lash; Lindsay J Collin; Miriam E Van Dyke
Journal:  Curr Epidemiol Rep       Date:  2018-04-12

5.  Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis.

Authors:  Thomas R P Taylor; James Galloway; Rebecca Davies; Kimme Hyrich; Ruth Dobson
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-04-16

Review 6.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

7.  Predictors of Multiple Sclerosis Severity Score in Patients with Multiple Sclerosis.

Authors:  Ahmed N Albatineh; Raed Alroughani; Rabeah Al-Temaimi
Journal:  Int J MS Care       Date:  2020-01-13

8.  Multiple sclerosis in Kenya: Demographic and clinical characteristics of a registry cohort.

Authors:  Imran Jamal; Jasmit Shah; Peter Mativo; Juzar Hooker; Mitchell Wallin; Dilraj Singh Sokhi
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-06-14

9.  Factors associated with physical, psychological and social frailty among community-dwelling older persons in Europe: a cross-sectional study of Urban Health Centres Europe (UHCE).

Authors:  Lizhen Ye; Liset E M Elstgeest; Xuxi Zhang; Tamara Alhambra-Borrás; Siok Swan Tan; Hein Raat
Journal:  BMC Geriatr       Date:  2021-07-12       Impact factor: 3.921

10.  Liver kinase B1 rs9282860 polymorphism and risk for multiple sclerosis in White and Black Americans.

Authors:  Anne I Boullerne; Mitchell T Wallin; William J Culpepper; Heidi Maloni; Elizabeth A Boots; Dagmar M Sweeney; Douglas L Feinstein
Journal:  Mult Scler Relat Disord       Date:  2021-08-02       Impact factor: 4.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.